Ph1/2 AAV5-RPGR (Botaretigene Sparoparvovec) Gene Therapy Trial in RPGR-associated X-linked Retinitis Pigmentosa (XLRP)

Michel Michaelides,1,* Cagri G. Besirli,2† Yesa Yang,1 Sui Chien Wong,3 Jose Sahel,4 Syed Mahmood Shah,4 Neruban Kumaran,1 Rachel Huckfeldt,5 Jason Comander,5 Anastasios Georgiadis,6 Stuart Naylor,6 Jialin Xu,7 Michael Clark,7 Eddy Anglade,7 Peggy Wong,7 Penny Fleck,7 Alexander Smith,1 Caterina Ripamonti,8 Robin Ali,1 Alexandria Forbes,6 James Bainbridge1

1UCL Institute of Ophthalmology, London, UK; 2Kellogg Eye Center, Ann Arbor, MI, USA; 3Moorfields Eye Hospital, London, UK; 4University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 5Harvard Medical School, Boston, MA, USA; 6MeiraGTx, New York, NY, USA; 7Janssen Pharmaceuticals, Raritan, NJ, USA; 8Cambridge Research Systems, Rochester, UK.

*Presenter.
†Current affiliation: Janssen Pharmaceuticals, Raritan, NJ, USA.

Presented at the American Academy of Ophthalmology (AAO) Retina Subspecialty Day; October 1, 2022.
Financial Disclosures

Michel Michaelides, MD (presenter)

- **Consultant**: Acucela, Stargazer Pharmaceuticals, 2C Tech, MeiraGTx, Janssen Pharmaceuticals
- **PI**: Acucela, ProQR, MeiraGTx
- **Equity ownership**: MeiraGTx
MGT009: Phase 1/2 Trial of AAV5-RPGR

Open-label study of an AAV5-RPGR gene therapy (NCT03252847) conducted at 5 sites in the **US and UK**

**Dose-escalation phase**
- Adults
  - Low dose (n = 3)
  - Intermediate dose (n = 4)
  - High dose (n = 3)

**Dose confirmation**
- Intermediate dose (n = 3)

**Expansion cohort**
- Adults and children
  - Followed for 12 months
    - Low dose (n = 8)
    - Intermediate dose (n = 11)

**Key inclusion criteria:**
- Males aged ≥5 years
- With RP caused by disease-causing variants in *RPGR*
- SD-OCT evidence of relative preservation of retinal structure at the macula
- Able to undertake age-appropriate clinical assessments

**Primary endpoint:** Safety

**N = 32**

R† 1:1:1 randomization.

*RPGR*, retinitis pigmentosa GTPase regulator; *RP*, retinitis pigmentosa; *SD-OCT*, spectral domain optical coherence tomography.
Clinical Safety in MGT009

- Doses for the expansion cohort were selected based upon the balance of safety and activity observed in the dose-escalation phase of the study.
- AAV5-RPGR gene therapy demonstrated an AE profile that is anticipated and manageable.
- Most AEs were related to the surgical delivery procedure, transient, and resolved without intervention.
- Dose-escalation phase SAEs (previously reported):
  - 1 retinal detachment: related to study procedure and resolved with treatment, with no sequelae.
  - 1 panuveitis (low dose).
- Dose-expansion phase SAE:
  - 1 increased intraocular pressure, resolved on treatment.
- No dose-limiting events.
- Following the implementation of a modified prophylactic steroid regimen for the expansion phase, there was a reduction in inflammation-related AEs in the expansion phase of the study.

Number of participants with ocular inflammation-related AEs by severity of AE:

<table>
<thead>
<tr>
<th>Severity of AE</th>
<th>Without Triamcinolone</th>
<th>With Triamcinolone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>16</td>
<td>8</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Severe</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

AE, adverse event; RPGR, retinitis pigmentosa GTPase regulator; SAE, serious adverse event.

Improvement in MRS in Pooled Low and Intermediate Doses Across All Adult Cohorts at 6 Months Observed: Static Perimetry and Microperimetry

| Parameter                  | Dose                                | Dose escalation + expansion§   | Sensitivity analysis applying phase 3 criteria†,# |
|----------------------------|-------------------------------------|--------------------------------|-------------------------------------------------
|                            | N        | LS mean change | Treated – concurrent control difference (±95% CI)‡ | N        | LS mean change | Treated – concurrent control difference (±95% CI)‡ |
| **Static perimetry**       |          |                |                                              |          |                |                                              |
| MRS10°                    | Pooled low + intermediate           | 24   | 2.41  | 1.96 (0.59, 3.34)* | 22   | 2.56  | 2.42 (0.91, 3.93)** |
|                           | Concurrent control                   | 13   | 0.45  |                  | 11   | 0.14  |                  |
| **Microperimetry**         |          |                |                                              |          |                |                                              |
| MRS-Scotopic Red           | Pooled low + intermediate           | 15   | 0.88  | 1.06 (0.05, 2.07)* | 15   | 0.88  | 1.06 (0.05, 2.07)* |
|                           | Concurrent control                   | 7    | –0.15 |                  | 7    | –0.15 |                  |

§Full analysis set population (observed data). Includes participants randomized to intermediate and given high dose.
†Participants excluded when applying phase 3 criteria.
‡Sensitivity analysis dataset is the same dataset as for the full analysis. Microperimetry was not available at all sites.
‡Adjusted for baseline, 2-sided nominal P value.
*Nominal P value < 0.05.
***Nominal P value < 0.001.

CI, confidence interval; LS, least squares; MRS, mean retinal sensitivity.
Improvement in Pointwise Responder Analysis of Static Perimetry in Pooled Low and Intermediate Doses Across All Adult Cohorts

<table>
<thead>
<tr>
<th>Week</th>
<th>Week 26†</th>
<th>Week 52‡</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Full analysis set§</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pooled low + intermediate</td>
<td>6/23 (26%)</td>
<td>11/23 (48%)</td>
</tr>
<tr>
<td>Concurrent control</td>
<td>2/10 (20%)</td>
<td></td>
</tr>
</tbody>
</table>

|                         |          |          |
| **Sensitivity analysis¶** |          |          |
| Pooled low + intermediate | 5/21 (24%) | 10/21 (48%) |
| Concurrent control | 0/8 (0%) |          |

*RPGR*, retinitis pigmentosa GTPase regulator.
†Week 26: number of participants who completed assessments at both week 26 and week 13. Week 52: number of participants who completed assessments at week 52 and ≥1 visit prior to week 52.
‡For concurrent control participants, this table only summarizes data prior to AAV5-hRKp.*RPGR* administration and serves as a control group. These participants were treated after week 26. There are no week 52 data for these participants.
§Full analysis set (observed data). Included participants randomized to intermediate and given high dose.
¶Participants excluded when applying phase 3 criteria.

Responder criteria: at least a 7 dB improvement from baseline in ≥5 individual loci, with the same 5 loci showing improvement at 2 time points following treatment.
Functional Vision Assessment: Mobility Maze

Dose-escalation Phase


- Light level: 1 lux
- Baseline performance: 61.7 seconds with 2 errors
- 9-month performance: 16.4 seconds with no errors

Participant 01-007  Maze assessment shown at 9-month time point.

To view the maze assessment please click [here](link).

---

**Significant Improvement in Walk Time at Week 26 Compared to Baseline**

Pooled Dose-escalation and Dose-expansion Treatment Difference Compared to Control at 6 Months (Change From Baseline ±95% CI)

Improvement

Treatment difference (Rx-c)

Nominal $P$ value for the full analysis $P < 0.05$ shown here.

All 3 lux levels had nominal $P$ values $<0.01$ after application of phase 3 criteria.

CI, confidence interval.
Conclusions

• AAV5-\textit{RPGR} gene therapy demonstrated an adverse event profile that is anticipated and manageable

• Efficacy assessments in this proof-of-concept study demonstrated that eyes treated with AAV5-\textit{RPGR} improved in retinal sensitivity and functional vision in comparison with randomized controls at 6 months
  • Sensitivity analysis on applying the phase 3 criteria further corroborated the endpoints selected for phase 3
  • In addition, all domains in the LLQ-PRO trended positively, and the extreme lighting domain was nominally significant (nominal $P<0.01$), which is consistent with VMA findings

• Further development of this therapy is warranted

• A phase 3 study of AAV5-\textit{RPGR} is underway (\textbf{NCT04671433})

LLQ, low luminance questionnaire; PRO, patient-reported outcome; \textit{RPGR}, retinitis pigmentosa GTPase regulator; VMA, visual mobility assessment.
Acknowledgments

• Participants and families
• Referring clinicians and collaborators
• Trial managers, coordinators, and technicians
• Reading centers in Belfast, OHSU, and MCW
• Other supporting institutions: Kellogg Eye Center (University of Michigan), Moorfields Eye Hospital (NHS Foundation Trust), UCL Institute of Ophthalmology, The Leeds Teaching Hospital (NHS Trust), Mass Eye and Ear (Mass General Brigham)
• Trial funding: MeiraGTx and Janssen

MCW, Medical College of Wisconsin; NHS, National Health Service; OHSU, Oregon Health and Science University; UCL, University College London.